↓ Direkt till sidans innehåll
↓ Direkt till sidans sekundära innehåll (sidomenyn)

Träfflista för sökning "WFRF:(BOCCARDO F) srt2:(2015-2019)"

Sökning: WFRF:(BOCCARDO F) > (2015-2019)

Resultat 1-5 av 5

Sortera/gruppera träfflistan

Sortering: Träffar per sida:

Numrering	Referens	Omslagsbild	Hitta
1.	Alberro, JA, et al. (författare) Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials 2018 Ingår i: The Lancet. Oncology. - 1474-5488. ; 19:1, s. 27-39 Tidskriftsartikel (refereegranskat)
2.	Boddington, C, et al. (författare) Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials 2019 Ingår i: Lancet (London, England). - 1474-547X. ; 393:10179, s. 1440-1452 Tidskriftsartikel (refereegranskat)
3.	Lee, B. B., et al. (författare) IUA-ISVI Consensus for diagnosis guideline of chronic lymphedema of the limbs 2015 Ingår i: International Angiology. - 1827-1839. ; 34:4, s. 311-332 Tidskriftsartikel (övrigt vetenskapligt/konstnärligt)
4.	Crawford, E. David, et al. (författare) FSH suppression and tumour control in patients with prostate cancer during androgen deprivation with a GnRH agonist or antagonist 2018 Ingår i: SCANDINAVIAN JOURNAL OF UROLOGY. - : Medical Journals Sweden AB. - 2168-1805 .- 2168-1813. ; 52:5-6, s. 349-357 Tidskriftsartikel (refereegranskat)abstract Background: Gonadotropin releasing hormone (GnRH) antagonists suppress follicle-stimulating hormone (FSH) to lower levels than GnRH agonists. This may partially explain the differences between these agents on prostate cancer outcomes. In this post-hoc analysis, FSH and prostate specific antigen (PSA) responses and the impact of cross-over from leuprolide to degarelix were evaluated from a 1-year comparative study (CS21) and its extension study (CS21A). Materials and methods: Overall, 610 patients were enrolled in CS21, wherein PSA and FSH levels were evaluated monthly. CS21A evaluated 386 patients, including those previously treated with degarelix (n = 251) who continued to receive degarelix, and those previously treated with leuprolide (n = 135) who crossed-over to receive degarelix. PSA and FSH levels were evaluated in CS21A for 3 months after cross-over. The associations between measurements were assessed using Spearman's correlation coefficient. The impact of class variables on FSH suppression were evaluated using Analysis of Variance. Results: Rapid PSA and FSH suppression was observed and maintained in the degarelix arm (CS21 and CS21A), while patients on leuprolide experienced rising PSA during CS21. Patients crossed-over from leuprolide to degarelix achieved a suppression of FSH and a significant PSA decrease. PSA and FSH levels were significantly (p < .05) correlated at months 1, 3, 6, 12 and 13 in the degarelix arm. Conclusions: Significant FSH suppression with GnRH antagonists may explain its advantage over GnRH agonists in terms of better prostate cancer control. The effect of profound FSH suppression is analogous to the need for profound testosterone suppression for tumor control.
5.	Pivetta, E, et al. (författare) Local inhibition of elastase reduces EMILIN1 cleavage reactivating lymphatic vessel function in a mouse lymphoedema model 2016 Ingår i: Clinical science (London, England : 1979). - 1470-8736. ; 130:14, s. 1221-1236 Tidskriftsartikel (refereegranskat)

Skapa referenser, mejla, bekava och länka

Länka till träfflistan

Resultat 1-5 av 5

Avgränsa träffmängd

Typ av publikation: tidskriftsartikel (5)

Typ av innehåll: refereegranskat (4); övrigt vetenskapligt/konstnärligt (1)

Författare/redaktör: Boccardo, F (4); Cameron, D. (2); Wang, X. (2); Bergh, J (2); Gnant, M. (2); Whelan, T. (2); visa fler...; Martin, M. (2); Hill, C. (2); Mackey, J. (2); Davies, C (2); Wilcken, N (2); Di Leo, A (2); Dolci, S (2); Berry, D (2); Broadwater, G (2); Cirrincione, C (2); Muss, H (2); Norton, L (2); Weiss, RB (2); Cuzick, J (2); Gray, R (2); Peto, R (2); Wood, W (2); Bartelink, H (2); van de Velde, CJH (2); von Minckwitz, G (2); Fountzilas, G (2); Arriagada, R (2); Coates, A (2); Forbes, J (2); Goldhirsch, A (2); Pater, JL (2); Pritchard, KI (2); A'Hern, R (2); Yarnold, JR (2); Albain, K (2); Shan, Y (2); Shao, YF (2); Zhao, DB (2); De Laurentiis, M (2); De Placido, S (2); Harbeck, N (2); Bartlett, JMS (2); Viale, G (2); Ewertz, M. (2); Bamia, C (2); Barlow, W (2); Bliss, J (2); Carrasco, E (2); Hayes, D (2); visa färre...

Lärosäte: Karolinska Institutet (3); Lunds universitet (2); Göteborgs universitet (1)

Språk: Engelska (5)

Forskningsämne (UKÄ/SCB): Medicin och hälsovetenskap (3)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

Copyright © LIBRIS - Nationella bibliotekssystem
LIBRIS.kb.se

pil uppåt

Stäng

Kopiera och spara länken för att återkomma till aktuell vy